Effect of HDAC inhibitor and GCV combination treatment on other EBV⁺ lymphoma cells. (A) Analysis of promoter use by the 3 different EBV lymphoma cell lines used in the study. Reverse transcription and PCR analysis of total RNA was carried out using primers that specifically detected the Qp, Wp, or Cp transcripts (Table 2). Products were analyzed on a 2% agarose gel with a 100-bp DNA ladder as a marker. A vertical line has been inserted to indicate a repositioned gel lane. (B) Effect of combination treatment on the BL line Daudi. Four hundred thousand cells/mL/well were used along with 60μM GCV in the appropriate wells. Assay parameters were as described in the legend for Figure 2. (C) Effect of combination treatment on the EBV-transformed lymphoblastoid cell line JY. In this case, 200 000 cells/mL/well were used, along with 60μM GCV as appropriate. Experiments were repeated 3 times and error bars represent SDs in individual experiments.